Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2–18 years: an updated systematic review and meta-analysis

World Journal of Pediatrics, Journal Year: 2023, Volume and Issue: 19(11), P. 1041 - 1054

Published: Feb. 1, 2023

Language: Английский

---

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

Eurosurveillance, Journal Year: 2023, Volume and Issue: 28(47)

Published: Nov. 23, 2023

Introduction The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim We aimed to measure VE against PCR-confirmed SARS-CoV-2 patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 July 2022 (Omicron-dominant period). Methods In both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. defined complete primary series vaccination (PSV) first booster dose as last of either received 14 days before symptom onset (stratifying into < 150 after PSV dose). measured overall, by category/product, age group time mRNA dose, adjusting site fixed effect, swab date, age, sex, presence/absence at least one commonly collected chronic condition. Results included 2,779 cases 2,362 controls. all products combined hospitalisation for laboratory-confirmed was 43% (95% CI: 29–54) (with onset), while it 59% 51–66) addition dose. 85% 78–89), 70% 61–77) 36% 17–51) those 14–59 days, 60–119 120–179 vaccination, respectively. Conclusions Our results suggest that, during the Omicron period, observed SARI improved particularly having 120

Language: Английский

---

Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece

Vaccine, Journal Year: 2023, Volume and Issue: 41(14), P. 2343 - 2348

Published: Feb. 2, 2023

Language: Английский

---

Optimal Timing of Vaccination: A Narrative Review of Integrating Strategies for COVID-19, Influenza, and Respiratory Syncytial Virus

Infectious Diseases and Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: April 9, 2025

Lower respiratory tract infections caused by SARS-CoV-2, influenza, and syncytial virus (RSV) cause a significant disease burden globally, despite the availability of effective vaccines. Certain populations, such as older adults (≥ 60 years) individuals all ages with particular comorbidities, are at increased risk for severe outcomes, including hospitalization death. National administration schedules available vaccines against viruses not unified, current guidelines clear directive, concerning optimal timing vaccination. Herein, we formulate an evidence-based position regarding COVID-19, RSV vaccination chronic based on synthesis literature guidelines. Vaccination impact were found to be influenced vaccinee factors, age waning vaccine effectiveness seasonal pathogen burden. Because display unique patterns within between regions, local epidemiological surveillance each is crucial determining To maximize benefits these vaccines, peak period greatest outcomes should aligned. Thus, other recommended given ahead start season (or regionally appropriate time) co-administered single, routine visit represent approach protecting at-risk populations. More data will required establish clinical benefit additional doses whether may integrated schedule. Coordinated policy decisions that align strain selection new annually reformulated would enable timely raising public health awareness, ultimately leading enhanced uptake. Implementation strategies require engagement healthcare providers strong, recommendations schedules.

Language: Английский

---

COVID-19 Vaccination Effectiveness in the General Population of an Italian Province: Two Years of Follow-Up

Vaccines, Journal Year: 2023, Volume and Issue: 11(8), P. 1325 - 1325

Published: Aug. 4, 2023

We carried out a cohort study on the overall population of province Pescara, Italy, to assess real-world effectiveness SARS-CoV-2 vaccination against infection, severe, or lethal COVID-19, two years after start campaign. included all resident domiciled subjects, and extracted official demographic, vaccination, hospital co-pay exemption datasets from 1 January 2021, up 15 February 2023. Cox proportional hazards analyses were adjusted for gender, age, diabetes, hypertension, COPD, major cardio- cerebrovascular events, cancer, kidney diseases. Throughout follow-up (466 days average), 186,676 subjects received greater than equal three vaccine doses (of ChAdOx1 nCoV-19, BNT162b2, mRNA-1273, NVX-CoV2373, JNJ-78436735), 47,610 doses, 11,452 one dose, 44,989 none. Overall, 40.4% infected with SARS-CoV-2. Of them, 2.74% had severe (1.30%) COVID-19. As compared unvaccinated, individuals who booster dose showed ≥85% lower risk A massive impact was found among elderly: 22.0% died, as opposed less 3% those doses. No protection infection observed, although this finding certainly influenced by Italian restriction policies control pandemic. Importantly, during Omicron predominance period, only group at least reduced COVID-19-related death.

Language: Английский

---

COVID-19 vaccine effectiveness and digital pandemic surveillance in Germany (eCOV study): App-based prospective observational cohort study (Preprint)

Journal of Medical Internet Research, Journal Year: 2024, Volume and Issue: 26, P. e47070 - e47070

Published: March 22, 2024

Background The COVID-19 pandemic posed significant challenges to global health systems. Efficient public responses required a rapid and secure collection of data improve the understanding SARS-CoV-2 examine vaccine effectiveness (VE) drug safety novel vaccines. Objective This study (COVID-19 on vaccinated unvaccinated subjects over 16 years; eCOV study) aims (1) evaluate real-world vaccines through digital participatory surveillance tool (2) assess potential self-reported for monitoring key parameters in Germany. Methods Using web application, we collected between May 1, 2021, August 2022, VE, test positivity rates, incidence adverse events after vaccination. Our primary outcome measure was VE against laboratory-confirmed infection. secondary measures included hospitalization across different variants, vaccination, symptoms during Logistic regression models adjusted confounders were used estimate 4 48 weeks vaccination series third-dose Unvaccinated participants compared with age- gender-matched who had received 2 doses BNT162b2 (Pfizer-BioNTech) those 3 not infected before last To data, official from authorities. Results We enrolled 10,077 (aged ≥16 y) contributed 44,786 tests 5530 symptoms. In this young, primarily female, digital-literate cohort, infections any severity waned 91.2% (95% CI 70.4%-97.4%) at week 37.2% 23.5%-48.5%) second dose BNT162b2. A third increased 67.6% 50.3%-78.8%) weeks. low number reported hospitalizations limited our ability calculate hospitalization. Adverse consistent previously published research. Seven-day incidences rates reflected course Germany when numbers national infectious disease system. Conclusions indicate that vaccinations are safe effective, partially restore protection showcased successful use application continuous Germany, highlighting its accelerate decision-making. Addressing biases is vital ensure accuracy reliability solutions as tools.

Language: Английский

---

A Narrative Review of Key Risk Factors for Severe Illness Following SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus Infection

Infectious Diseases and Therapy, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 30, 2024

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza, and syncytial virus (RSV) are highly infectious viruses that affect people of all ages typically associated with mild symptoms few complications in immunocompetent individuals. However, the risk severe outcomes (e.g., hospitalization death) following infection these is higher certain populations, including older adults individuals race/ethnic sociodemographic groups. Additionally, immunocompromising conditions pre-existing comorbidities, underlying cardiovascular congestive heart failure) diseases chronic obstructive pulmonary disease), diabetes, kidney disease, obesity, key factors predispose to SARS-CoV-2-, influenza-, RSV-related outcomes. Increased for advancing age comorbidities compounded by residence long-term care facilities due enhanced spread infections congregate living environments. In this narrative review, SARS-CoV-2, RSV adult populations explored. distinct clinical based on discussed context high-risk populations. Factors unique each underpin profiles described suggest potential tailored surveillance healthcare approaches target ultimately mitigate RSV-associated disease burden vulnerable Mutual also highlighted; similarities indicate cohesive reduction strategies may be feasible, particularly since vaccines available viruses. Ultimately, a more thorough understanding develop improve strategies, inform policy, contribute expansion refinement existing

Language: Английский

---

A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine

Vaccine, Journal Year: 2024, Volume and Issue: 42(22), P. 126165 - 126165

Published: Aug. 27, 2024

The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) Working Group evaluates the safety and other key features new platform technology vaccines, including nucleic acid (RNA DNA) vaccines. This manuscript uses BRAVATO template to report considerations for a benefit-risk assessment coronavirus disease 2019 (COVID-19) mRNA-based vaccine BNT162b2 (Comirnaty®, or Pfizer-BioNTech COVID-19 vaccine) subsequent Original/Omicron BA.1, BA.4-5 Omicron XBB.1.5 variant-adapted vaccines developed BioNTech Pfizer protect against caused severe acute respiratory syndrome 2 (SARS-CoV-2). Initial Emergency Use Authorizations conditional Marketing original were granted based upon favorable taking into account clinical safety, immunogenicity, efficacy data, which was subsequently reconfirmed younger age groups, real world evidence data. In addition, maintained bivalent newly arising SARS-CoV-2 variants, with accumulating trial

Language: Английский

---

How Does the Public Receive Information about Vaccines during the COVID-19 Pandemic? A Nationwide Cross-Sectional Study in Spain

Societies, Journal Year: 2023, Volume and Issue: 13(3), P. 62 - 62

Published: March 9, 2023

Spain has been one of the most severely impacted countries by COVID-19. Vaccination against COVID-19 is successful preventive strategies. However, some citizens show vaccine resistance, in part due to widespread disinformation that disseminated since pandemic’s start. The objective this study was explore characteristics Spanish population terms their use traditional and social media for vaccine-related information. A countrywide survey conducted June 2022 following a descriptive cross-sectional analysis. Respondents declared 80.4% had received full schedule vaccination, over 60% would take booster dosage without hesitation. major reasons not having were possible health risks (37%), lack trust vaccines (29%). More than 85% respondents closely followed news on topic, with journalistic (27%) authorities (26%) considered be important sources pandemic information, while 9% respondents. Further collaboration between professionals, as well campaigns enhance vaccination uptake dose, might future

Language: Английский

---

Effectiveness of various COVID-19 vaccine regimens among 10.4 million patients from the National COVID Cohort Collaborative during Pre-Delta to Omicron periods – United States, 11 December 2020 to 30 June 2022

Vaccine, Journal Year: 2023, Volume and Issue: 41(42), P. 6339 - 6349

Published: Sept. 22, 2023

Language: Английский

---